WIWataru Izumo

Wataru Izumo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wataru Izumo has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Masakazu Yamamoto

    Gastrointestinal Surgery, Utsunomiya Memorial Hospital, 1-3-16, Odori, Utsunomiya, Tochigi, 320-0811, Japan

    13 shared publications
  • Masakazu Yamamoto

    Institute of Gastroenterology, Tokyo Women’s Medical University

    12 shared publications
  • Shuichiro Uemura

    Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    12 shared publications
  • Masahiro Shiihara

    Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    11 shared publications
  • Ryota Higuchi

    Department of Surgery, Institute of Gastroenterology Tokyo Women's Medical University Tokyo Japan

    11 shared publications
  • Takehisa Yazawa

    Gastrointestinal Surgery, Utsunomiya Memorial Hospital, Utsunomiya, Tochigi, Japan

    9 shared publications

Latest Publications

  • Prognostic Significance of Serum Tumor Markers According to the Timing of Recurrence After Curative Esophagectomy for Esophageal Squamous Cell Carcinoma

    by Akihito Mizukami, Suguru Maruyama, Katsutoshi Shoda, Yoshihiko Kawaguchi, Yuto Saegusa, Taishu Oka, Takaomi Ozawa, Hiroto Tanaka, Ryo Saito, Wataru Izumo, et al.

    Background: Reliable biomarkers for predicting post‐recurrence survival in esophageal squamous cell carcinoma (ESCC) remain limited. We evaluated the prognostic significance of three serum tumor markers routinely used in clinical practice (carcinoembryonic antigen [CEA], squamous cell carcinoma antigen [SCC], and serum p53 antibody [p53‐Ab]) in patients with recurrent ESCC after curative esophagectomy. Methods: Sixty patients who developed recurrence after curative resection for ESCC were retrospectively analyzed. Overall survival (OS) after recurrence was compared according to serum CEA, SCC, and p53‐Ab levels measured at recurrence. Exploratory subgroup analyses were performed according to the timing of recurrence. Results: Elevated SCC levels at recurrence were significantly associated with worse post‐recurrence OS ( p < 0.01), whereas CEA and p53‐Ab levels were not. Multivariable analysis identified elevated SCC as an independent predictor of poor post‐recurrence survival (hazard ratio, 2.50; 95% confidence interval, 1.18–5.33; p = 0.02). In the exploratory analysis according to recurrence timing, elevated SCC levels were associated with worse survival among patients with standard recurrence ( p < 0.01), whereas no significant associations were observed for CEA or p53‐Ab. Among patients with late recurrence, elevated p53‐Ab levels showed a possible association with poorer survival ( p = 0.05). Conclusions: Serum SCC measured at recurrence may serve as a prognostic biomarker for post‐recurrence survival in patients with ESCC after curative esophagectomy. Exploratory analyses according to recurrence timing suggested that SCC may be particularly relevant in standard recurrence, whereas p53‐Ab showed a possible prognostic association in late recurrence.

  • Open Access

    To Evaluate Whether Pretreatment CA19 ‐9 and DUPAN ‐2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer

    by Hiromichi Kawaida, Wataru Izumo, Ryo Saito, Hidetake Amemiya, Suguru Maruyama, Katsutoshi Shoda, Kensuke Shiraishi, Shinji Furuya, Yoshihiko Kawaguchi, Daisuke Ichikawa

    Aim: Pancreatic cancer (PC) remains one of the most lethal malignancies, with early recurrence severely affecting prognosis even after curative resection. While neoadjuvant treatments (NAT), such as gemcitabine plus S‐1 (NAT‐GS), have improved outcomes, predicting their effectiveness and optimizing patient selection remain challenging. This study aimed to investigate whether pretreatment CA19‐9 and DUPAN‐2 levels can serve as predictive markers to guide the choice between NAT and upfront surgery in pancreatic cancer. Methods: We retrospectively analyzed 190 patients with PC (67 with NAT‐GS and 123 with upfront surgery). Patients were stratified into three groups based on their pre‐NAT CA19‐9/DUPAN‐2 levels: both within the reference range, one exceeding, or both exceeding. The 12 month recurrence‐free survival (12MRFS) rates were assessed using the Kaplan–Meier method, with log‐rank and other appropriate statistical tests for comparison. Results: NAT‐GS was significantly more effective only in patients with one tumor marker above the reference range, comparing those who achieved 12 month MRFS with those who did not. In the Kaplan–Meier curve, among patients with only one elevated tumor marker, the NAT‐GS group showed a significantly better 12MRFS ratio than the upfront surgery group (78.6% vs. 51.2%, p = 0.034). Conclusion: The combination of pre‐NAT CA19‐9 and DUPAN‐2 levels may serve as a useful criterion for selecting between upfront surgery, NAT‐GS, or more intensive chemotherapy. This suggests the possibility of a tailored approach, in which a combination of tumor markers would determine whether to opt for upfront surgery, NAT‐GS, or more intensive chemotherapy.

  • Open Access

    Impact of Circular Stapler Size on Short‐Term Outcomes and Long‐Term Quality of Life After McKeown Esophagectomy

    by Suguru Maruyama, Katsutoshi Shoda, Yoshihiko Kawaguchi, Ryo Saito, Wataru Izumo, Kensuke Shiraishi, Shinji Furuya, Hidetake Amemiya, Hiromichi Kawaida, Daisuke Ichikawa

    Background: The circular stapling technique (CST) is reported to be a simple and time‐efficient method; however, it is associated with a high incidence of anastomotic stenosis for McKeown esophagectomy. Meanwhile, the impact of circular stapler size remains controversial. We aimed to investigate the impact of circular stapler size on both short‐term outcomes and long‐term quality of life (QOL) after McKeown esophagectomy. Methods: In total, 63 consecutive patients who underwent McKeown esophagectomy for esophageal cancer between 2019 and 2022 were eligible. We examined the association between circular stapler size and short‐term outcomes and long‐term QOL using the PGSAS‐37. Results: 35 (55.6%) patients underwent anastomosis with a 21 mm stapler, whereas 28 (44.4%) patients used a 23 mm stapler. No significant differences were observed between the groups. The incidence of anastomotic leakage did not differ significantly between the groups (5.7% vs. 7.1%, p = 1.00) Also, the incidence of anastomotic stenosis did not differ between the groups (25.7% vs. 21.4%, p = 0.77). However, in QOL assessment, the meal‐related subscale (SS) score in the 21 mm group was significantly worse than in the 23 mm group ( p = 0.02). Regarding the details the meal‐related SS score, the feeling of dysphagia was significantly worse in the 21 mm group ( p < 0.01). Conclusions: Short‐term outcomes did not differ between patients who underwent anastomosis with a 21 mm stapler and those with a 23 mm stapler, however QOL, particularly the feeling of dysphagia, was worse in patients who used a 21 mm stapler compared to those who used a 23 mm stapler.

  • Non-operative observational strategy for small non-functioning pancreatic neuroendocrine neoplasms: A feasible option?

    by Wataru Izumo, Ryota Higuchi, Toru Furukawa, Takehisa Yazawa, Shuichiro Uemura, Masahiro Shiihara, Masakazu Yamamoto, Goro Honda

  • Open Access

    Clinically Adult-Onset Nesidioblastosis with Repeated Severe Hypoglycemia, Successfully Treated by Two Times Pancreatectomies. A Rare Case Report

    by Wataru Izumo, Ryota Higuchi, Masahiro Shiihara, Shuichiro Uemura, Takehisa Yazawa, Noriyoshi Takano, Atsuhiro Ichihara, Toru Furukawa, Yoji Nagashima, Masakazu Yamamoto, et al.

    Although nesidioblastosis is the most common cause of hyperinsulinemic hypoglycemia in infants, it is rare in adults. Nesidioblastosis is pathologically characterized by diffuse neoformation of the islets of Langerhans islets from the pancreatic ductal epithelium and is a disease that does not exhibit neoplastic proliferation, unlike insulinoma. Hence, we present a rare case of adult-onset nesidioblastosis that caused repeated severe hypoglycemic symptoms and was cured by pancreatic resection twice, resulting in total pancreatectomy. A 37-year-old woman with the Whipple’s triad visited our institution. In the fasting test, the plasma glucose level decreased and immunoreactive insulin levels increased after 12 h. No tumor was identified in the pancreas by imaging. A selective arterial calcium injection test revealed that step-up was detected only in the gastroduodenal artery. The patient underwent pancreatoduodenectomy with a diagnosis of adult-onset nesidioblastosis, with the pancreatic head region as the culprit. Pathological examination revealed neither tumorous islet cells nor an obvious increase in the number of islets. However, there were some isolated single insulin-producing cells in the pancreatic parenchyma, which could cause hyperinsulinemia and hypoglycemia. This patient was diagnosed with adult-onset nesidioblastosis. After the operation, the hypoglycemic symptoms improved, but 1 year later, the same symptoms recurred. The patient underwent remnant pancreatectomy and had no hypoglycemic symptoms for > 5 years after the second surgery.


  • Open Access

    A Case of Pathologically Complete Response After Nivolumab Combined with Chemotherapy in a Gastric Cancer Patient with Virchow’s Lymph Node Metastasis

    by Wataru Izumo, Kei Hosoda, Hidekazu Kuramochi, Go Nakajima, Shinsuke Maeda, Shunichi Ito, Yoji Nagashima, Michio Itabashi

    Gastric cancer with Virchow’s lymph node metastasis (LNM) is not indicated for initial curative surgery. Although there have been some case reports of curative resections after pre-operative treatment, including immune checkpoint inhibitors (ICIs), there is no consensus regarding the optimal timing of surgery. We describe a rare case of initially unresectable gastric cancer treated preoperatively with nivolumab combined chemotherapy, which achieved a pathologically complete response. An 82-year-old man was referred for gastric cancer treatment. Contrast-enhanced computed tomography revealed stomach wall thickening and swollen left supraclavicular LN. This gastric cancer was assessed as unresectable due to the presence of Virchow’s LNM; therefore, chemotherapy and ICI using S-1 plus oxaliplatin plus nivolumab were administered. After three courses of treatment, the primary tumor and Virchow’s LN showed a marked reduction in size. The patient underwent Virchow’s LNM resection as a preliminary step to determine indications for curative surgery. A pathological examination revealed no viable cancer cells were found inside the resected LN. The patient underwent distal gastrectomy. Pathological examination revealed complete degeneration of the primary tumor and regional LN without residual carcinoma. The patient did not receive adjuvant chemotherapy and survived with no evidence of recurrence for one year after the initial treatment.


  • Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms

    by Wataru Izumo, Ryota Higuchi, Toru Furukawa, Takehisa Yazawa, Shuichiro Uemura, Yutaro Matsunaga, Masahiro Shiihara, Yukiko Takayama, Junko Tahara, Kyoko Shimizu, et al.

    Background: Some prognostic factors for pancreatic neuroendocrine neoplasms (PanNENs) have been reported; however, the significance of lymphatic, microvascular, and perineural invasion remains unclear. We aimed to clarify the role of these factors in PanNEN recurrence. Patients and Methods: We analyzed 138 patients who underwent curative pancreatectomy and were pathologically diagnosed with PanNEN. We evaluated the association between clinicopathological factors and the recurrence of PanNENs. Results: The numbers of patients with lymphatic, microvascular, and perineural invasion were 34 (25%), 43 (31%) and 17 (12%), respectively. Twenty-four patients (17%) had recurrences, and the 3, 5, and 10-year recurrence-free survival (RFS) rates were 88%, 84%, and 76%, respectively. The recurrence sites (with duplication) were mainly the liver (twenty-two patients), followed by the lymph nodes (seven patients), and bone (two patients). In multivariate analyses, grade 2-3 and the presence of microvascular invasion were significant risk factors for RFS (hazard ratio=7.5 and 7.9, respectively). When examining outcomes according to these factors, the 5-year RFS rates of patients with risk scores of 0, 1, and 2 were 100%, 91%, and 32%, respectively (p<0.001). Even in patients with grade 1 (n=97) or limited resection (enucleation, splenic-preserving distal pancreatectomy, central pancreatectomy, and duodenum-preserving pancreatic head resection, n=62), the presence of microvascular invasion was a significant risk factor for RFS (hazard ratio=13.4 and 18.0, respectively). Conclusion: The presence of microvascular invasion is an independent risk factor for recurrence in patients with PanNEN.


  • A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis

    by Wataru Izumo, Ryota Higuchi, Toru Furukawa, Takehisa Yazawa, Shuichiro Uemura, Yukiko Takayama, Kyoko Shimizu, Katsutoshi Tokushige, Hiroto Egawa, Masakazu Yamamoto

    Preoperative treatment is being proposed as a standard treatment for pancreatic ductal adenocarcinoma though few cases show a pathologically complete response. On the other hand, there is no consensus regarding preoperative chemotherapy for pancreatic acinar cell carcinoma (ACC). The present study described a rare case of ACC in the pancreatic head with portal vein tumor thrombosis (PVTT) treated with preoperative chemotherapy using modified FOLFIRINOX, which achieved a pathologically complete response. A 65-year-old man was referred for consideration of treatment strategy. Contrast-enhanced abdominal computed tomography revealed a pancreatic tumor and PVTT. The pancreatic tumor was diagnosed as ACC by an endoscopic ultrasound-guided fine-needle aspiration biopsy. Initially, the tumor was assessed as unresectable due to the presence of PVTT, and therefore, a chemotherapy using modified FOLFIRINOX was administered. After 14 courses of the chemotherapy, imaging studies revealed that the tumor and PVTT showed marked reduction in size; thus, the patient underwent pancreaticoduodenectomy with combined resection of the portal vein (PV). A pathological examination uncovered a complete degeneration of the primary tumor and the PV embolus without any residue of carcinoma. The patient did not receive adjuvant chemotherapy and survived with no evidence of recurrence for 33 months after surgery. The chemotherapy using modified FOLFIRINOX could give a complete response in patients with pancreatic ACC with PVTT.


  • Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel

    by Wataru Izumo, Ryota Higuchi, Toru Furukawa, Takehisa Yazawa, Shuichiro Uemura, Yutaro Matsunaga, Masahiro Shiihara, Masakazu Yamamoto

    Background: Gemcitabine together with nab-paclitaxel (GnP) has been shown to improve outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). However, the predictive markers for treatment effects remain unclear. This study aimed to identify early prognostic factors in patients with PDAC receiving GnP. Patients and Methods: We analyzed 113 patients who received GnP for PDAC and evaluated the relationship between clinical factors and outcomes. Results: The median survival time (MST) was 1.2 years. In multivariate analysis, baseline carbohydrate antigen 19-9 (CA19-9) ≥747 U/ml [hazard ratio (HR)=1.9], baseline controlling nutrition status (CONUT) score ≥5 (HR=3.7) and changing rate of CA19-9 after two GnP cycles ≥0.69 (HR=3.7) were independent risk factors for poor prognosis. When examining outcomes according to pre-chemotherapeutic measurable factors (baseline CA19-9 and CONUT), the MSTs of patients with pre-chemotherapeutic zero risk factors (pre-low-risk group, n=63) and one or more risk factors (pre-high-risk group, n=50) were 1.7 and 0.65 years (p<0.001), respectively. The MST for those with a changing rate of CA19-9 after two GnP cycles <0.69 and ≥0.69 was significantly different in both groups (2.0 and 1.2 years in the pre-low-risk group, p<0.001; 1.0 and 0.52 years in the pre-high-risk group, p<0.001). Conclusion: These results may be useful for decision-making regarding treatment strategies in patients with PDAC receiving GnP.


  • Resectional surgery in gallbladder cancer with jaundice—how to improve the outcome?

    by Rahul K. Chaudhary, Ryota Higuchi, Takehisa Yazawa, Shuichirou Uemura, Wataru Izumo, Yutaro Matsunaga, Erika Nagano, Yasuto Sato, Takehiro Ota, Toru Furukawa, et al.

    Purpose To evaluate the surgical outcomes of patients with gallbladder cancer (GBC) with jaundice due to as-yet unelucidated prognostic factors. Methods A total of 348 GBC patients underwent resection at our institute between 1985 and 2016. Of these, 67 had jaundice (serum total bilirubin ≥ 2 mg/dL). Preoperative biliary drainage was performed, with portal vein embolization as required. All patients underwent radical surgery. We retrospectively evaluated the outcomes, performed multivariate analysis for overall survival, and compared our findings to those reported in the literature. Results The 5-year survival rate of M0 (no distant metastasis) GBC patients with jaundice, who underwent resectional surgery, was 21.9%, versus 68.3% in those without jaundice (p < 0.05). Since 2000, surgical mortality in GBC patients with jaundice has decreased from 12 to 6.8%. Patients with jaundice had more advanced disease and underwent major hepatectomies and vascular resections; however, preoperative jaundice alone was not a prognostic factor. Multivariate analysis of jaundiced patients revealed that percutaneous biliary drainage (PTBD) (vis-à-vis endoscopic drainage [EBD], hazard ratio [HR] 2.82), postoperative morbidity (Clavien–Dindo classification ≥ 3, HR 2.31), and distant metastasis (HR 1.85) were predictors of poor long-term survival. The 5-year survival and peritoneal recurrence rates in M0 patients with jaundice were 16% and 44%, respectively, for patients with PTBD and 39% (p < 0.05) and 13% (p = 0.07) for those with EBD. Conclusion M0 GBC patients with jaundice should undergo surgery if R0 resection is possible. Preoperative EBD may be superior to PTBD in M0 GBC patients with jaundice, although further studies are needed.